Category Archives: Biochemistry

Faculty of medicine researchers attract more than $21M in CIHR Fall 2020 funding – UBC Faculty – UBC Faculty of Medicine

Faculty of medicine researchers have attracted more than $21 million in funding from the Canadian Institutes of Health Research (CIHR).

In all, 354 research grants were funded for a total investment of approximately $274 million through the Project Grants: Fall 2020 competition. In addition, 97 priority announcement grants were funded to a total amount of $9,575,000 and 11 supplemental prizes were awarded for a total of $296,500.

UBC researchers attracted a total of $25.6 million for 41 projects. Thirty-three UBC-led projects received Project Grant funding totalling $24.8 million and eight UBC-led projects received priority announcement grants totalling $775,000.

Douglas Allan, department of cellular and physiological sciences

Project: Transcriptional programs of synapse maturation

CIHR Funding: $856,800 (5 years)

Ali Bashashati, School of Biomedical Engineering;Peter Black, department of urologic sciences;Larry Goldenberg, department of urologic sciences

Project: Prostate cancer risk stratification for active surveillance using computer-aided analysis of histopathology and transcriptomics

CIHR Funding: $906,525 (5 years)

Colin Collins, department of urologic sciences

Project: Uncovering early mediators of lineage plasticity and validation of a metabolic vulnerability in neuroendocrine prostate cancer

CIHR Funding: $1,147,500 (5 years)

Angela Devlin, department of pediatrics;Pascal Bernatchez,department of anesthesiology, pharmacology and therapeutics;Constadina Panagiotopoulos, department of pediatrics

Project: Correcting early vascular dysfunction to improve cardiovascular outcomes in type 1 diabetes

CIHR Funding: $841,500 (5 years)

Quynh Doan,department of pediatrics

Project: Evaluating the psychometric properties and help-seeking impact of HEARTSMAP-U: a digital psychosocial self-assessment and navigational support application for post-secondary students.

CIHR Funding: $554,624 (4 years)

Nichole Fairbrother, department of psychiatry

Project: Perinatal Anxiety Disorders Screening Study

CIHR Funding: $684,676 (4 years)

David Fedida, department of anesthesiology, pharmacology and therapeutics

Project: Mechanisms of potassium channel activator action on Kv7.1 ion channel complexes.

CIHR Funding: $971,550 (5 years)

Brian Grunau, department of emergency medicine;Jane Buxton, School of Population and Public Health;James Christenson, department of emergency medicine

Project: Opioid Overdose-Related Cardiac Arrest: What are the Best Interventions?

CIHR Funding: $283,051 (3 years)

Joerg Gsponer, department of biochemistry and molecular biology;Lawrence Mcintosh, department of biochemistry and molecular biology

Project: Protein phase separation: A new mechanism of protein function regulation in Mycobacterium tuberculosis

CIHR Funding: $887,400 (5 years)

Jaime Guzman, department of pediatrics

Project: Treating Children with Arthritis According to their Individual Probability of Outcomes and Response to Treatments The PERSON-JIA Trial

CIHR Funding: $455,175 (5 years)

Nicholas Bansback, School of Population and Public Health

Project: Evaluating the impact of a mandatory switching policy for biosimilars

CIHR Funding: $298,350 (3 years)

Rob Holt, department of medical genetics

Project: Lentiviral infusion as a universal approach for genetically modified immune effector cell therapies.

CIHR Funding: $642,600 (4 years)

Rosemin Kassam, School of Population and Public Health

Project: Women supporting women using local solutions to improve infant and young child feeding and care practices in Punjab, Pakistan

CIHR Funding: $799,425 (5 years)

Christian Kastrup, department of biochemistry and molecular biology

Project: Minimally-invasive device and bioabsorbable hemostatic powder for managing non-compressible torso hemorrhage

CIHR Funding: $455,176 (4 years)

Jayachandran Kizhakkedathu, pathology and laboratory medicine;Dirk Lange, department of urologic sciences

Project: Novel Infection Resistant Coating in an Era of Drug Resistant Bacteria for the Treatment and Prevention of Medical Device Infection

CIHR Funding: $520,199 (3 years)

Rodney Knight, department of medicine

Project: Identifying the impact of cannabis use on mental health outcomes among sexual and gender minority youth: A mixed-methods study

CIHR Funding: $478,126 (3 years)

Chinten James Lim, department of pathology and laboratory medicine

Project: Targeting CD47 in pediatric acute lymphoblastic leukemia.

CIHR Funding: $1,028,925 (5 years)

Teresa Liu-AmbroseandLinda Li, department of physical therapy

Project: SuPA Mobility: Supporting Physical Activity to Promote Mobility in Mobility-Limited Older Adults

CIHR Funding: $631,128 (6 years)

Martin Mckeown, department of medicine, division of neurology

Project: In silico Design of Precision Electrical Stimuli for Electrical Vestibular Stimulation in Parkinsons Disease.

CIHR Funding: $841,270 (5 years)

Robert Molday, department of biochemistry and molecular biology

Project: High Resolution Structure of Human ABCA4, an ATP-binding Cassette (ABC) Lipid Importer Associated with Inherited Retinal Degenerative Diseases

CIHR Funding: $918,000 (5 years)

Melanie Murray, department of medicine

Project: Role of Female Sex Hormones on Aging in Women Living with HIV.

CIHR Funding: $382,500 (5 years)

Ivan Nabi, department of cellular and physiological sciences

Project: Using super-resolution microscopy to define the role of caveolin-1 in cancer

CIHR Funding: $910,350 (5 years)

Nobuhiko Tokuriki, department of biochemistry and molecular biology

Project: Novel antibiotic therapies that target bacterial energetic systems

CIHR Funding: $956,250 (5 years)

Michael Underhill, department of cellular and physiological sciences

Project: Tissue-resident mesenchymal progenitors and aging

CIHR Funding: $971,550 (5 years)

Cheryl Wellington, department of pathology and laboratory medicine;Angela Brooks-Wilson, department of medical genetics);Ging-Yuek Robin Hsiung, department of medicine

Project: Evaluating the potential of blood biomarkers to improve Alzheimers Disease risk stratification

CIHR Funding: $1,503,224 (4 years)

Christian Steidl, department of pathology and laboratory medicine

Project: Somatic mutations in the JAK-STAT and IRF signaling pathways in Non-Hodgkin lymphoma

CIHR Funding: $1,120,725 (5 years)

Glen Tibbits, department of pathology and laboratory medicine

Project: Catecholaminergic polymorphic ventricular tachycardia (CPVT): arrhythmogenic mechanisms and personalized intervention

CIHR Funding: $924,120 (5 years)

Jan Dutz, department of dermatology and skin science

Project: Phototherapy to modulate regulatory T cells and prevent autoimmune disease

CIHR Funding: $382,499 (3 years)

Kendall Ho, department of emergency medicine

Project: Technologies for Home Medication Vigilance and Protection (TEC4Home MVP)

Priority Announcement: Health Services and Policy Research

CIHR Funding: $50,000 / Canadian Medical Association (Ottawa) Funding: $50,000

Brodie Sakakibara, department of occupational science and occupational therapy

Project: Advancing virtual care in stroke rehabilitation: TeleRehabilitation with Aims to Improve Lower Extremity Recovery Post-Stroke (TRAIL)

Priority Announcement: Health Services and Policy Research

CIHR Funding: $50,000 / Canadian Medical Association (Ottawa) Funding: $50,000

Wendy Norman, department of family practice

Project: The CART PREG-Epi Study: Pandemic Reproductive health and health Equity- Guidance from Epidemiology to improve reproductive, perinatal, and maternal mental health and substance use care

Priority Announcement: Population and Public Health Public Health Systems

CIHR Funding: $100,000

Patricia Janssen, School of Population and Public Health

Continue reading here:
Faculty of medicine researchers attract more than $21M in CIHR Fall 2020 funding - UBC Faculty - UBC Faculty of Medicine

Repeated Doses of Ketamine Affect the Infant Rat Urogenital System | DDDT – Dove Medical Press

Hulya Kaskara,1 Nuran Sungu,2 Mustafa Arslan,3 Aysegul Kucuk,4 Levent Ozturk,5 Nigar Afandiyeva,6 Mustafa Kavutcu6

1Department of Anaesthesiology and Reanimation, Ankara City Hospital, Ankara, Turkey; 2Medical Faculty, Department of Pathology, Yldrm Bayazit University, Ankara, Turkey; 3Medical Faculty, Department of Anaesthesiology and Reanimation, Gazi University, Ankara, Turkey; 4Medical Faculty, Department of Physiology, Kutahya Health Sciences University, Kutahya, Turkey; 5Medical Faculty, Department of Anaesthesiology and Reanimation, Yldrm Bayazit University, Ankara, Turkey; 6Medical Faculty, Department of Biochemistry, Gazi University, Ankara, Turkey

Correspondence: Mustafa ArslanMedical Faculty, Department of Anesthesiology and Reanimation, Gazi University, Ankara, 06510, TurkeyTel +90 312 202 6739Email mustarslan@gmail.com

Aim: Long-term ketamine use is known to create an interstitial cystitis-like problem in the bladder. It is known that long-term intermittent ketamine is applied to the children receiving radiotherapy for sedation. This study was planned to investigate whether this effect seen in the bladder causes similar changes in the kidneys, testicles, epididymis and ductus deferens.Materials and Methods: A total of 12 male Wistar Albino rats for 3 weeks were used in the study. Rats were divided equally into 2 groups as, ketamine and saline. 50 mg/kg ketamine was administered intraperitoneally during 21 days to ketamine (K) groups. 1mL/kg saline was administered intraperitoneally during 21 days to saline (S) groups. At the end of 21 days kidney and testicular tissues were taken for biochemical and histopathological evaluations.Results: Histological assessment of kidney tissue showed that tubule epithelial congestion increased significantly in the ketamine group. Epididymis congestion and distortion in the epididymal gland were found to be different in the ketamine group when testicular tissue was examined. Thiobarbituric acid reactive substances (TBARS) level in testicular and kidney tissue was found to be significantly higher in the ketamine group according to the saline group. Catalase (CAT) enzyme activity was significantly lower in the ketamine group compared to the saline group in both tissues. Paraoxonase-1 (PON-1) enzyme activity was significantly higher in the ketamine group compared to the saline group.Conclusion: We think that the results we have achieved in this study will provide guidance on ketamine, which is repeated in daily anesthesia applications, especially in radiation oncology. But these findings should be supported by clinical and experimental studies that will be conducted in a more detailed and broad series.

Keywords: ketamine, infant rat, testicular tissue, kidney, epididymis

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

View original post here:
Repeated Doses of Ketamine Affect the Infant Rat Urogenital System | DDDT - Dove Medical Press

Mississippi State hosts Miss Maroon and White Pageant themed ‘A Midsummer Night’s Dream’ – Mississippi State Newsroom

Contact: Landon Gibson

STARKVILLE, Miss.Twenty-four students will compete for the title of Miss Maroon and White 2021 at Mississippi State University on Saturday [March 13].

The winner will be selected alongside four Maroon and White beauties at a public program in historic Lee Halls Bettersworth Auditorium. The event begins at 7:30 p.m., with doors opening at 7 p.m.

Admission is $15 for the general public and $10 for MSU students with current I.D. Tickets are available through the Center for Student Activities in Colvard Student Union, Suite 314 or online athttps://msstate.universitytickets.com/w/event.aspx?id=1461.

In addition to Mississippi, this years contestants represent Alabama and Tennessee. They include (by hometown):

BRANDONShelby G. Freeman, a senior marketing major; and Holley K. Yates, a junior accounting major.

CARRIEREJessie V. Besanson, a senior biochemistry major.

COLLIERVILLE, TennesseeChanning E. Perrett, a sophomore biological science major.

COMOSarrah C. Stephenson, a junior animal and dairy sciences major.

CORINTHRachel G. Carpenter, a junior accounting major.

EUPORAChloe S. Vaughn, a senior communication major.

HATTIESBURGBlakeley E. Baudoin, a sophomore biochemistry major.

HOUSTONAddyson C. Crump, a freshman elementary education major.

KOSCIUSKOAdyson D. Poole, a junior landscape architecture major.

MACONStephanie D. Kauffman, a senior educational psychology major.

MADISONSavannah M. Richardson, a junior elementary education major; Abby E. Vance, a freshman food science, nutrition and health promotion major; and Camille Waller, a freshman communication major.

MADISON, AlabamaDacey T. Burgess, a freshman elementary education major; and Elisa S. Castaeda, a junior architecture major.

MERIDIANTaylor C. Cook, a junior communication major.

MOBILE, AlabamaMadeleine I. Thompson, a sophomore communication major.

MURFREESBORO, TennesseeAinsley E. Gordon, a senior biological sciences major.

NESBITKennedi L. Pigues, a senior accounting major.

OXFORDMary Paxton Heiskell, a freshman food science, nutrition and health promotion major.

RICHTONCamille E. Green, a senior wildlife, fisheries and aquaculture major.

RIDGELANDCandice R. Bruce, a sophomore communication major.

SEBASTOPOLLydia B. Bishop, a junior communication major.

MSU is Mississippis leading university, available online at http://www.msstate.edu.

See the article here:
Mississippi State hosts Miss Maroon and White Pageant themed 'A Midsummer Night's Dream' - Mississippi State Newsroom

Semi Automatic Biochemistry Analyzer Sales Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 | Top Players…

Making accurate business decisions is always a tough task. However, if the company has acquired proper insights about the market, making those decisions becomes easy. DataIntelo offers the right support any business requires in the form of its meticulous research reports.

DataIntelo has rolled out a novel report on the Global Semi Automatic Biochemistry Analyzer Sales Market. The report is filled with imperative insights on the market which will support the clients to make accurate business decisions. This research will help both existing and new entrants for the Semi Automatic Biochemistry Analyzer Sales market to figure out and study market essentials, market size, and competition. The report is integrated with data regarding the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities, and the threats encountered by key players during the forecast period of 2020-2027.

Some of the major companies that are covered in this report:

*Note: Additional companies can be included on request

Request a sample before buying this report @ https://dataintelo.com/request-sample/?reportId=262719

Impact of COVID-19 on Semi Automatic Biochemistry Analyzer Sales market

The report has also crucial insights regarding the impact of the ongoing global crisis i.e. COVID-19 on the Semi Automatic Biochemistry Analyzer Sales market and explains how the future is going to unfold for the market in the coming years. The report also provides an in-depth analysis of the effects of the pandemic on the global economy. The outbreak has directly influenced production and disrupted the demand and supply chain. The report also calculates the financial impact on firms and financial markets. DataIntelo has gathered insights from various delegates of the industry and performed the primary and secondary research to include strategies into the report in order to combat the market challenges during and after the COVID-19 pandemic.

Industry experts and research analysts have worked extensively to fabricate the research report which will give that extra edge to our clients business in the competitive market. The market research report can be customized as per any requirement. This means that DataIntelo can cover a particular product, application, or can offer a detailed analysis in the report. DataIntelo also offers separate report for a specific region.

You can buy the complete report in PDF format @ https://dataintelo.com/checkout/?reportId=262719

Merits of buying the report:

The market scenario is likely to be fairly competitive. To analyze any market with simplicity the market is fragmented into the following segments:

By Applications:

By Types:

By Regions:

Segmenting the market into smaller components helps in analyzing the dynamics of the market with more clarity. Another key component that is integrated into the report is the regional analysis to assess the global presence of the Semi Automatic Biochemistry Analyzer Sales market. You can also opt for a yearly subscription to all the updates on the Semi Automatic Biochemistry Analyzer Sales market.

Major questions answered in the report:

If you have any questions about this report, feel free to reach us! @ https://dataintelo.com/enquiry-before-buying/?reportId=262719

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Semi Automatic Biochemistry Analyzer Sales Market Overview

Global Semi Automatic Biochemistry Analyzer Sales Market Analysis and Forecast by Type

Global Semi Automatic Biochemistry Analyzer Sales Market Analysis and Forecast by Application

Global Semi Automatic Biochemistry Analyzer Sales Market Analysis and Forecast by Sales Channel

Global Semi Automatic Biochemistry Analyzer Sales Market Analysis and Forecast by Region

North America Semi Automatic Biochemistry Analyzer Sales Market Analysis and Forecast

Latin America Semi Automatic Biochemistry Analyzer Sales Market Analysis and Forecast

Europe Semi Automatic Biochemistry Analyzer Sales Market Analysis and Forecast

Asia Pacific Semi Automatic Biochemistry Analyzer Sales Market Analysis and Forecast

Asia Pacific Semi Automatic Biochemistry Analyzer Sales Market Size and Volume Forecast by Application

Middle East & Africa Semi Automatic Biochemistry Analyzer Sales Market Analysis and Forecast

Competition Landscape

About DataIntelo:

DataIntelo has vast experience in making customized market research reports in many industry verticals. Our motto is to provide complete client satisfaction. We cover in-depth market analysis, which consists of stipulating lucrative business strategies, especially for the new entrants and the emerging players of the market. We make sure that each report goes through intensive primary, secondary research, interviews, and consumer surveys before final dispatch.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also offer ongoing training and knowledge sharing to keep our analysts tapped into industry best practices and loaded with information.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

https://neighborwebsj.com/

Follow this link:
Semi Automatic Biochemistry Analyzer Sales Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 | Top Players...

In-vitro Diagnostics (IVD) Market to Reach $118.5 Billion by 2027, Growing at a CAGR of 7% from 2020 with the Increasing Demand for Infectious Disease…

London, March 10, 2021 (GLOBE NEWSWIRE) -- In-vitro diagnostic (IVD) testing has become an indispensable tool in clinical practice for diagnosing and monitoring diseases, providing prognosis, and predicting treatment response. The IVD industry is growing steadily due to various factors such as increased demand for infectious disease testing as new pathogen strains develop each year and high incidences of hospital acquired infections. The IVD market comprises of kits & reagents, system, and software and services which can be used to detect diseases or other conditions and can be used to monitor a person's overall health to help cure, treat, or prevent diseases.

Thein-vitro diagnostics (IVD) market is projected to reach $118.5 billion by 2027, at a CAGR of 7% from 2020. The growth in this market is primarily driven by the rising prevalence of acute & chronic infectious diseases, increasing funding for research activities, growing awareness for early disease diagnosis, the shift in the focus from centralized to point-of-care testing, and the emergence of the COVID-19 pandemic. Further, the emerging economies, development of condition-specific markers and tests, and advances in genomics and proteomics are expected to offer significant growth opportunities for players operating in the IVD market.

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=4858

The in-vitro diagnostics (IVD) market is segmented based on product & solution, technology, application, end user, and geography.

Based on product and solution, the in-vitro diagnostics (IVD) market is broadly segmented into kits &reagents, instruments, and software and services. In 2020, the kits & reagents segment accounted for the largest share of the overall in-vitro diagnostics (IVD) market. The large share of this segment is primarily attributed to the frequent use of assays & kits in the detection of various chronic diseases, commercial availability of a diverse range of reagents & consumables for various diseases diagnosis, increase in the volume of testing for infectious diseases such as COVID-19 and influenza, and rise in demand of molecular and immunoassay reagents across the globe.

Based on technology, the in-vitro diagnostics (IVD) market is segmented into immunoassay/ immunochemistry, molecular diagnostics, biochemistry/clinical chemistry, microbiology, hematology, coagulation/hemostasis, urinalysis, and other technologies, which include hybridization and loop mediated amplification. In 2020, the immunoassay/ immunochemistry segment accounted for the largest share of the overall in-vitro diagnostics (IVD) market due to the increase in the prevalence of infectious diseases, the exponential rise in the number of diagnostic tests for COVID-19, and rise in the number of approvals and emergency use authorizations of COVID-19 test kits & reagents. However, the molecular diagnostics segment is expected to grow at the fastest CAGR during the forecast period due to rising awareness of personalized medicine and companion diagnostics, advancements in molecular techniques, rising focus of market players on the development of diagnostic NGS kits & reagents and rising penetration of cutting-edge clinical laboratory technologies.

Quick Buy In-vitro Diagnostics Market Research Report:https://www.meticulousresearch.com/Checkout/85135759

Based on application, the in-vitro diagnostics (IVD) market is segmented into infectious diseases, oncology, cardiology, endocrinology, diabetes, nephrology, and other applications, which include toxicology, gastrology, neonatal, genetic, and neurological disorders.

In 2020, the infectious diseases segment accounted for the largest share of the overall IVD market. The large share of this segment is primarily attributed to the recent regulatory approvals, product launches, increase in the availability of COVID-19 test kits across the globe, and the growth of the infectious diseases segment. However, the oncology segment is expected to grow at the fastest CAGR during the forecast period due to the adoption of various strategies for increasing access to new diagnostic technologies in oncology by IVD manufacturers, the growing influx of new products for cancer diagnosis owing to the rising prevalence of cancer, and growing field of personalized medicine in oncology.

Based on the end user, the in-vitro diagnostics (IVD) market is broadly segmented into diagnostics reference laboratories, hospitals and clinics, home healthcare, and other end users, including nursing homes, academic and research institutes, forensic laboratories, and transfusion laboratories. In 2020, the diagnostics reference laboratories segment commanded the largest share of the overall IVD market. The large share of this segment is primarily attributed to the rising numbers of samples shared with laboratories for analysis, rising laboratory automation, availability of well-equipped systems, presence of skilled laborers, rise in the number of patient volume owing to the emergence of various infectious diseases, and government initiatives to support the technological advancements of laboratories.

Based on geography, the in-vitro diagnostics (IVD) market is categorized into five major regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with a further analysis of major countries in these regions.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business:https://www.meticulousresearch.com/speak-to-analyst/cp_id=4858

In 2020, North America commanded the largest share of the global IVD market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The rising prevalence of various infectious diseases, the growing healthcare sector, increasing awareness regarding early disease diagnosis, higher adoption for advanced innovative diagnostic products, and increasing funding activities coupled with novel advanced diagnostic technologies contribute to the growth.

Some of the key players operating in the in-vitro diagnostics (IVD) market are Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), bioMrieux S.A. (France), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), DiaSorin S.p.A. (Italy), Ortho Clinical Diagnostics (U.S.), Siemens Healthcare GmbH (Germany), Sysmex Corporation (Japan), QIAGEN N.V. (Netherlands) among others.

To gain more insights into the market with a detailed table of content and figures, click here:https://www.meticulousresearch.com/product/ivd-market-4858

Scope of the Report:

In-vitro Diagnostics Market, by Product & Solution

In-vitro Diagnostics Market, by Technology

In-vitro Diagnostics Market, by Application

In-vitro Diagnostics Market, by End User

In-vitro Diagnostics Market, by Geography

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=4858

Amidst this crisis, Meticulous Researchis continuously assessing the impact of the COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here-https://www.meticulousresearch.com/custom-research

Related Reports-

In Vitro Diagnostic (IVD) Reagents Market by Type (Antibodies, Oligonucleotide, Nucleic Acid Probe), Technology (Immunoassay, Hematology, Microbiology), Use (Research, Analyte Specific Reagent), End User (IVD Manufacturer, Clinical Laboratory) - Global Forecast to 2027

https://www.meticulousresearch.com/product/in-vitro-diagnostic-reagents-market-5110

Infectious Disease Diagnostics Market by Product and Solution (Consumables, System, Software and Services), Technology (Immunodiagnostics, PCR, INAAT), Disease (HIV, HAIS, Influenza), End User (Hospital, Reference Lab, Research) - Global Forecast to 2027

https://www.meticulousresearch.com/product/infectious-disease-diagnostics-market-4976

Influenza Diagnostics Market by Test Type {[Traditional (RIDT, Direct Fluorescent Antibody, Viral Culture, Serology), Molecular [RT-PCR, INAAT (NASBA, LAMP)]}, End User (Hospitals, Laboratories, Academics, Research Institutes) - Global Forecast to 2027

https://www.meticulousresearch.com/product/influenza-diagnostics-market-5099

Immunoassay Market by Product (Kits and Reagents, Analyzers, Software), Platform (Chemiluminescence, Radioimmunoassays) Application (Infectious Diseases, Cardiology), End User (Hospitals, Academic Laboratories), and Geography - Global Forecast to 2025

https://www.meticulousresearch.com/product/immunoassay-market-4982

About Meticulous Research

Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to detail. With meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact:Mr. Khushal BombeMeticulous ResearchDirect Lines: +1-646-781-8004 (North America)+44-203-868-8738 (Europe)+91 744-7780008 (Asia-Pacific)Email-sales@meticulousresearch.comVisit Our Website:https://www.meticulousresearch.com/Connect with us on LinkedIn-https://www.linkedin.com/company/meticulous-researchContent Source:https://www.meticulousresearch.com/pressrelease/198/ivd-market-2027

Continued here:
In-vitro Diagnostics (IVD) Market to Reach $118.5 Billion by 2027, Growing at a CAGR of 7% from 2020 with the Increasing Demand for Infectious Disease...

Global Biochemistry Analyzer Market Is Anticipated Grow Aggressively during 2020 to 2026 SoccerNurds – SoccerNurds

A recent Market Research Report byMarket Research Store, on Biochemistry Analyzer Market Overview By Trends, Size, Industry Top Manufacturers, Industry Growth Analysis & Forecast Till 2026 Flourishing data has been added to the collection to provide readers with detailed information about market developments, includes detailed market overview, seller scenario, market dimensions, as well as depth SWOT and PESTEL valuation, aside from other internationally approved market evaluation guidelines that play vital roles in growth of spreading information.

The report Biochemistry Analyzer Market 2020-2026, outlines and describes the key factors influencing market growth. It proposes an in-depth study of market heights (revenue), key market segment, market share, specific geographical regions, key market players and trends in vital industries. The purpose of this report is to describe the upcoming market trends and earnings forecasts in the global Biochemistry Analyzer market for the next five years.

We Have New Updates Of Biochemistry Analyzer Market In Sample Copy@https://www.marketresearchstore.com/report/global-biochemistry-analyzer-market-report-2020-by-key-774122#RequestSample

(A free sample of this report is immediately available upon request and is updated with the addition of new research).

What Benefits Does Market Research Store Research Study Is Going To Provide?

The Pre & Post Impact of COVID- 19 on Businesses.2021 Latest industry influencing trends and development scenarioTake advantage of powerful market opportunitiesImportant decisions in planning and market expansionIdentify essential Business Segments, Market proposition & Gap AnalysisHelping in allocating marketing investmentsMRS Research Methodology

Biochemistry Analyzer Market By Top Manufacturers (2021-2026)

Abbott, Agappe Diagnostics, HORIBA, RMS, Xylem Analytics, Labindia Instruments, Thermo Fisher Scientific, Siemens Healthcare, MicroLab Instruments

Request A Free PDF Brochure: To Get An Additional List Of Dominant Market Players Included In This Report:https://www.marketresearchstore.com/report/global-biochemistry-analyzer-market-report-2020-by-key-774122#RequestSample

Major Product Types Covered Are:

Semi Auto, Fully Auto

Major Applications of Biochemistry Analyzer Covered Are:

Hospital and Diagnostic Laboratories, Home Care, Academic and Research Institutes

On Some Of The Below Factors Market Player Analysis Is Based

COVID-19 Pre & Post Impact Analysis on Manufacturers profit, Revenue, and Sales.Company OverviewPrice, sales, revenue and Gross Margin AnalysisProduct portfolioRecent initiativesShare Analysis and Market Size

Lockdowns due to COVID-19 has affected economies and industries in various countries, also the businesses shutdowns and travel bans. Due to COVID-19 the decrease in the overall market growth is also affecting the Post growth of theBiochemistry Analyzer marketowing to the shutting down of factories, lots of obstacles in the supply chain, and a downturn in the world economy.

This report presents a complete overview, growth opportunities and market shares of Biochemistry Analyzer market by product type, key manufacturers, application and key regions and countries. In addition, the report discusses key producers, market developments, opportunities, challenges, and factors affecting large producers and the risks facing by the whole Biochemistry Analyzer market. It also analyze essential emerging trends and their effect on present and future developments.

Get Free Analysis Report Of Covid-19 Impact On Biochemistry Analyzer Market:https://www.marketresearchstore.com/report/global-biochemistry-analyzer-market-report-2020-by-key-774122#InquiryForBuying

Points Covered In The Report

The points discussed in the report are the vital market players that are involved in the market such as raw material suppliers, equipment suppliers, traders, end users distributors, etc.

The detailed profile of the companies is mentioned. And the capacity, production, capacity, cost, revenue, gross margin, sales volume, price, consumption, growth rate, future strategies, import, export, supply, and the technological developments that they are making are also included in the report. 12 years of data history and forecast is analyzed in this report.

The growth factors of the market are discussed where the different users of the market are described in detail.

According to specific requirements data and information by market player, by region, by type, by application, etc., and custom research can be added.

The SWOT analysis of the market within the report. The final of the report contains conclusion part where the industrial experts opinions are included.

Biochemistry Analyzer Market

The market research report also offers information about strategic growth market analysis, potential investment opportunities, and Potential risks that clients will follow to design business and business models and strategies. The essential data analysis in the Biochemistry Analyzer market report is provided in an upright way. This means that the information is represent in the form of statistics, infographics and uncomplicated graphs to make it more easier and time-saving task for the client.

The scope of Biochemistry Analyzer Market size reports range from broader market scenarios to comparative prices between key players, costs, and benefits of specific market segments. The numerical data is supported by statistical tools such as SWOT analysis, SCOT analysis, BCG matrix, and PESTLE analysis. The facts and figures are shown in graphical form in a clear picture.

Biochemistry Analyzer The report provides detailed information about the market and the strategic developments of various vital sellers. To know about the competitive landscape of the Biochemistry Analyzer market, an analysis of Porters five forces model is done.The study involves market attrition analysis with specific types, source types, and application segments based on market size, growth rate, and attrition.

Key strategic developments in theBiochemistry Analyzer marketcompetitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other significant activities by key players of the Biochemistry Analyzer market are well described in the report.

Customization Service Of The Report:

(*Please let us knowif any special requirements about this report, we can provide a custom report..*)

Table Of Contents

Executive SummaryResearch MethodologyAssumptions and Acronyms UsedMarket OverviewGlobal Market Analysis and Forecast, by ApplicationsGlobal Market Analysis and Forecast, by TypesGlobal Market Analysis and Forecast, by RegionsLatin America Market Analysis and ForecastNorth America Market Analysis and ForecastAsia Pacific Market Analysis and ForecastThe Middle East & Africa Market Analysis and ForecastEurope Market Analysis and ForecastCompetition Landscape

Research Coverage:

The Biochemistry Analyzer market has been segmented based on offering, technology, end-use application, and end-user. It also provides a complete view of the market across four main regions: North America, Europe, APAC, and RoW.

About Us

Market Research Store is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. Market Research Store is the comprehensive collection of market intelligence products and services available on air. We have market research reports from number of leading publishers and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.

The rest is here:
Global Biochemistry Analyzer Market Is Anticipated Grow Aggressively during 2020 to 2026 SoccerNurds - SoccerNurds

The future of science education: Q&A with the creator of a new chemistry course – Arizona Daily Wildcat

Laura Van Dorn is a professor at the University of Arizona. She currently teaches chemistry 101A and 101B. CHEM 101A is a general chemistry course and CHEM 101B is an introductory course to organic chemistry and biochemistry. Due to the pandemic, both classes have been switched to a live-online format.

Van Dorn has developed a new, challenging chemistry course: CHEM 130. It is designed to have a year's worth of general chemistry completed in a single semester. CHEM 130 is for students who need the foundations of chemistry and biochemistry, but given their career focus in different areas, will not necessarily go on to take additional chemistry classes. The Daily Wildcat sat down with Van Dorn via email to find out more about the process of starting a new course.

Daily Wildcat: Can you provide a brief description of CHEM 130?

Laura Van Dorn: CHEM 130 will introduce students in nursing and public health majors to the fundamental principles of general and organic chemistry and elements of biochemistry, with a focus on medical, nutritional, and environmental aspects of the discipline.

Current topics in health sciences will be used to guide students in developing a solid background in chemistry that may be applied in their future careers. Critical thinking and pattern recognition will be utilized with the goal of developing skills in problem-solving, applying the foundations of chemistry to new concepts.

Students will be taught to integrate their conceptual and modeling skills with quantitative data to make predictions regarding the behavior of molecules in different environments.

DW: What makes CHEM 130 different from other entry-level chemistry courses?

Van Dorn: CHEM 130 is a one-semester overview of the material, which other chemistry and biochemistry courses typically take several semesters to cover. It is the only course of this kind at UArizona.

It is designed for students who need a fundamental understanding of chemistry and biochemistry, but do not have room in their degree programs for the traditional 2 semesters of General chemistry, two semesters of Organic Chemistry, and two semesters of Biochemistry (which is what Chemistry or Biochemistry majors would normally take).

CHEM 130 will emphasize the elements of chemistry and biochemistry important to public health and nursing fields. It will introduce students to recognizing patterns and making predictions. Demonstrations and activities will be a large part of the course. It can be difficult to visualize some of the concepts in chemistry, thus being able to see the effects of chemicals on different types of matter has the tendency to help students.

DW: Do you recommend those only in the pre-health route to take CHEM 130?

Van Dorn: No, this course is for anyone with an interest in how chemistry applies to every aspect of our lives. Our bodies, our environment, all of it is chemistry.

DW: How would you describe the rigor of this course?

Van Dorn: CHEM 130 will be a challenging class, preparing students for careers in health-related fields. Although no extensive background in math or science will be required before taking the class, students should expect to invest considerable effort in mastering the material. Readings will be assigned before class, and students will complete weekly homework as well as unit assessments.

As the course will be offered in-person and through Arizona Online, students will be able to complete much of the course at their own pace. A three-unit science course does require time outside class, and motivation on the part of the students, but theyll learn some really interesting things.

DW: Is CHEM 130 going to be offered as an alternative for CHEM 151?

Van Dorn: CHEM 130 will be very different from CHEM 151 or its equivalent CHEM 141. CHEM 141 or 151 covers only the first half of General Chemistry. CHEM 130 will encompass all of General Chemistry (i.e. CHEM 141/151 plus CHEM 142/152), in addition to important elements of Organic Chemistry and Biochemistry.

The depths of coverage will, of course, be different, given the course objectives, its target audience, and time constraints, but it is important to stress that CHEM 130 is a much broader class than either CHEM 141 or CHEM 151. CHEM 141 or 151 are suitable for students that need chemistry as a prerequisite for higher-level chemistry classes and have a foundation in math.

DW: Is there anyone else you made and/or designed the class with?

Van Dorn: The course content is my own. I will be working with Celeste Atkins at Arizona Online in order to offer the class online as well as in-person for Fall 2021. Colleen Kelly will be developing the separate lab course, CHEM 130L.

Follow Briana Aguilar on Twitter

Let us come to you. The Daily Wildcat, straight to your inbox. News. Science/Health. Sports. Arts/Lifestyle. You choose. You cancel at any time.

See more here:
The future of science education: Q&A with the creator of a new chemistry course - Arizona Daily Wildcat

UW chemist and oceanographer named Sloan Fellows – UW News

News releases

February 16, 2021

Two faculty members at the University of Washington have been awarded early-career fellowships from the Alfred P. Sloan Foundation. The new Sloan Fellows, announced Feb. 16, areAshleigh Theberge, an assistant professor in the Department of Chemistry and Jodi Young, an assistant professor in the School of Oceanography.

Open to scholars in eight scientific and technical fields chemistry, computer science, economics, mathematics, molecular biology, neuroscience, ocean sciences and physics the fellowships honor those early-career researchers whose achievements mark them among the next generation of scientific leaders.

The 128 Sloan Fellows for 2021 were selected in coordination with the research community. Candidates are nominated by their peers, and fellows are selected by independent panels of senior scholars based on each candidates research accomplishments, creativity and potential to become a leader in their field. Each fellow will receive $75,000 to apply toward research endeavors.

This years fellows come from 58 institutions across the United States and Canada, spanning fields from evolutionary biology to data science.

Ashleigh Theberge

Theberge is an assistant professor of chemistry. Her research probes the chemical signals that cells use to communicate with one another. The organization of our bodies, with different types of cells taking on discrete functions, depends on this biochemical language.

Were alive because our cells can exchange chemical messages in appropriate ways, said Theberge, who is also an adjunct assistant professor of urology at the UW. All cells human cells, microbes utilize chemical signals to deliver information and influence the properties of other cells.

Jodi Young

Youngis an assistant professor in the School of Oceanography. She studies microbial oceanography, with a focus on the role of marine algae in the carbon cycle. In particular, her research explores polar ecosystems and other extreme environments, and the biochemistry of photosynthesis. Herresearchcombines fieldwork,algal culture manipulationsand biochemical and molecular analyses to uncover the evolution and adaptations of biological carbon fixation in the oceans.

Half of all photosynthesis happens in the oceans, across an amazingly diverse collection of organisms, Young said. My groups research focuses on understanding the underlying physiological and molecular adaptations of marine photosynthesis. Understanding how marine algae have and will adapt to a changing climatereveals insights into how life on Earth evolved and will respond in the future.

For more information, contact Theberge atabt1@uw.edu and Young at youngjn@uw.edu.

Originally posted here:
UW chemist and oceanographer named Sloan Fellows - UW News

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing…

NEW YORK, Feb. 18, 2021 /PRNewswire/ --Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced positive top-line data from an investigator-sponsored phase 2 proof-of-concept clinical trial of IMU-838 in primary sclerosing cholangitis (PSC). This single-arm, open-label, exploratory study was designed to investigate IMU-838's potential to improve various biochemical parameters in PSC patients and help determine whether any such activity warrants further investigation in randomized PSC trials. As previously announced, due to the COVID-19 pandemic, only 18 of the targeted 30 patients were enrolled in the study (intent-to-treat population, ITT), of whom only 11 patients completed the full IMU-838 treatment course and were evaluable over the 24-week treatment period (per-protocol population, PP).

The PP population experienced a statistically significant decrease in serum alkaline phosphatase (ALP) levels (p=0.041) after 24 weeks of treatment using 30 mg IMU-838 once daily, as compared to baseline. A consistent individual pattern of a stable decrease in ALP values was observed in the PP population between baseline and week 24, without any single patient showing an increase of more than 20% of ALP. As per the definition of the primary objective of the study, 27.3% of the patients in the PP population had a clinically relevant reduction of serum ALP higher than 25% at week 24, without an increase in liver biochemistry of more than 33%, as compared to baseline. Biochemical endpoints, such as changes in serum ALP, have been used in PSC trials performed by third parties.

Regarding the secondary objectives of the study, no changes in aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total, direct or indirect bilirubin were observed in the ITT or PP populations, as compared to baseline. In addition, despite the limited scope of the data, encouraging results were observed regarding symptoms of inflammatory bowel disease, a common comorbidity for PSC patients, and patient assessments of health-related quality of life. The study also found that IMU-838 is a safe and well-tolerated oral drug for PSC patients and treatment-emergent adverse events were rare and generally mild.

"I am very excited about the effects we have seen in this highly underserved patient population where there is only a small number of cases worldwide and where no pharmaceutical treatment option is currently available," noted Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "We are also very pleased to see that IMU-838's safety and tolerability profile was confirmed in this patient group. The results from this small, open-label study suggest that IMU-838 merits further clinical testing in PSC. We are in discussions with investigators and leading clinical experts to further evaluate the data set and to explore potential next steps for this indication."

"Currently, no effective treatment options are available for PSC patients and the hepatology community is very keen to see new approaches and clinical programs for the investigation of promising new approaches. I am grateful that Mayo Clinic and Immunic are collaboratively exploring this underserved indication for which liver transplantation is often the only effective option," stated Keith Lindor, M.D., Professor of Medicine Emeritus and former President of the American Association for the Study of Liver Diseases. "Although we are mindful of the small size of this dataset, I do believe the results are noteworthy and merit further exploration. Notable in this small patient cohort is the absolute consistency with which these patients experienced decreases in serum alkaline phosphatase at the 24-week time point."

Study Background and Baseline Characteristics

The single-arm, open label, exploratory study was an investigator-sponsored trial led by Elizabeth Carey, M.D., Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, who had received Investigator Investigational New Drug (IND) approval from the U.S. Food & Drug Administration (FDA) and had been granted Institutional Review Board (IRB) approval to conduct the study. The study was supported by a grant from the National Institutes of Health (NIH) and was conducted at two sites: Mayo Clinic, Phoenix, Arizona (Dr. Carey) and Mayo Clinic, Rochester, Minnesota (John E. Eaton, M.D.), both of which are tertiary referral centers for PSC patients.

The study, for which Immunic provided the study medication, planned to enroll 30 patients with PSC, aged 18 to 75 years, who received 30 mg of IMU-838 once daily for a period of 24 weeks. Enrollment for the study took place between July 2019 and September 2020, but almost all enrollment occurred in 2019 and early 2020. During the COVID-19 pandemic, recruitment for this study was hampered, as patients with PSC are at a high risk of COVID-19 infections and were advised to avoid travel and unnecessary social contacts such as those required to participate in a clinical trial. Together with the investigators, Immunic determined to readout data of the 18 patients who were enrolled prior to the COVID-19 pandemic. The ongoing COVID-19 pandemic also triggered the principal investigator's decision to terminate the study in late 2020, before the intended recruitment goal of 30 patients was reached.

A total of 18 patients started treatment of 30 mg IMU-838 once daily (intent-to-treat population, ITT, n=18). Of these 18 patients, 11 patients received the full 24-week treatment with IMU-838 (per-protocol population, PP, n=11). Due to the high number of discontinued patients during the COVID-19 pandemic and the fact that all discontinued patients in an ITT statistical analysis will be counted as treatment failures at week 24, this analysis focuses mainly on the 11-patient PP population.

Primary Objective

The primary objective of this study was to determine whether IMU-838 reduces serum ALP in adult patients diagnosed with PSC. The main analysis for the primary objective was whether patients could achieve a reduction of ALP at week 24 which is greater or equal to 25%, as compared to baseline, while the AST increase at week 24 is no more than 33%, as compared to baseline. This positive primary outcome was achieved by 3 of 11 patients in the PP population (27.3%, 95% CI: 6-61%). By virtue of inclusion criteria, patients at baseline had to have an elevated ALP value of at least 1.5 times upper limit of normal (ULN).

In addition, time from baseline was calculated as a continuous variable and treated as the primary predictor using a random intercept model which was adjusted for age at baseline and gender. For this longitudinal analysis of ALP from baseline to week 24 in the PP population, the ALP value statistically significantly (p=0.041) decreased by an average of 5.76 IU/L every 30 days (95% CI: -11.29, -0.23; statistical model). The time trend was not statistically significant in the ITT analysis (p=0.578) due to missing data following the high rate of treatment discontinuations during the COVID-19 pandemic.

Secondary Objectives

Secondary objectives were to investigate the liver biochemistry parameters, AST, ALT, and total/direct/indirect bilirubin, as well as the concentrations of proinflammatory cytokines, as compared to baseline. The longitudinal analysis of both AST and ALT as well as total, direct and indirect bilirubin values showed a stable pattern in the PP population with no statistically significant change over time and the confidence interval to include the no-change scenario (AST: average 30 day change 1.22 IU/L, 95% CI: -0.53, 2.97, p=0.170; ALT: average 30 day change 0.85 IU/L, 95% CI -1.46, 3.15, p=0.467, total bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.02, p=0.561, direct bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.861, indirect bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.556). Similar results were found in the ITT population. In addition, a decrease in the Ulcerative Colitis Clinical score was observed in evaluated patients, although the number of assessed patients was limited.

"This was a feasibility study to explore activity of IMU-838 in PSC patients based on biochemical parameters. IMU-838 was found to lead to a statistically significant reduction of serum ALP over time in the PP population, while no trend for increases in ALT, AST or bilirubin was observed," commented Andreas Muehler, M.D., Chief Medical Officer of Immunic. "Despite the challenges we faced due to COVID-19, which severely hindered the enrollment at the two Mayo Clinic sites and which led to an unusually high discontinuation rate and an early termination of the study, we have seen encouraging activity signals for IMU-838 in this patient population. Based on these promising data and, in particular, the improvement in biochemical liver parameters, we will continue to evaluate the potential of IMU-838 as a treatment option for PSC patients. It may also be worthwhile to optimize dose levels of IMU-838 in PSC patients in the future."

For more information on this clinical trial, please visit: http://www.clinicaltrials.gov, NCT03722576.

Conference Call and Webcast Information

As previously announced, Immunic's management team will host a public conference call and webcast today, February 18, 2021 at8:00 a.m. Eastern Timeto discuss the data from the main phase 2 analysis of the CALVID-1 trial of IMU-838 in hospitalized patients with moderate COVID-19, as well as data from the investigator-sponsored phase 2 clinical trial of IMU-838 in primary sclerosing cholangitis.

To participate in the conference call, dial 1-877-870-4263 (USA) or 1-412-317-0790 (International) and ask to be joined into the Immunic, Inc. call. A live, listen-only webcast of the conference call can be accessed at https://www.webcaster4.com/Webcast/Page/2301/39950or on the "Events and Presentations" section of Immunic's website at ir.imux.com/events-and-presentations.

An archived replay of conference call and webcast will be available approximately one hour after the completion for one year on Immunic's website at: ir.imux.com.

About Primary Sclerosing Cholangitis (PSC) PSC is a rare liver disease with a prevalence of approximately 4.15 per 100,000 in the United States, in which the bile ducts in the liver become inflamed, narrow and prevent bile from flowing properly. The exact cause and disease mechanism of PSC are still unknown, but an autoimmune mechanism may play a role. There is an association with inflammatory bowel diseases, most often with ulcerative colitis and less commonly with Crohn's disease. PSC is a progressive disease and, other than liver transplantation, there are currently no approved therapies that have been shown to improve survival in patients with PSC. The estimated time from diagnosis of PSC to death or liver transplant has been shown to be less than 15 years.

About IMU-838IMU-838 is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH). IMU-838 acts on activated T and B cells while leaving other immune cells largely unaffected and allows the immune system to stay functioning, e.g. in fighting infections. In previous trials, IMU-838 did not show an increased rate of infections compared to placebo. In addition, DHODH inhibitors, such as IMU-838, are known to possess a host-based antiviral effect, which is independent with respect to specific virus proteins and their structure. Therefore, DHODH inhibition may be broadly applicable against multiple viruses. IMU-838 was successfully tested in two phase 1 clinical trials in 2017 and is currently being tested in a phase 2 trial in patients with ulcerative colitis. In the third quarter of 2020, the company reported positive results from its phase 2 EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis, achieving both primary and key secondary endpoints with high statistical significance. In the first quarter of 2021, Immunic announced that IMU-838 has shown evidence of clinical activity in its phase 2 CALVID-1 trial in hospitalized patients with moderate COVID-19. Also, in the first quarter of 2021, the company reported positive top-line data from an investigator-sponsored phase 2 proof-of-concept clinical trial of IMU-838 in primary sclerosing cholangitis which was conducted in collaboration with Mayo Clinic. To date, IMU-838 has been tested in more than 800 individuals and has shown an attractive pharmacokinetic, safety and tolerability profile. IMU-838 is not yet licensed or approved in any country.

About Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company witha pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Immunic is developing three small molecule products: its lead development program,IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORt; and IMU-856 targets the restoration of the intestinal barrier function. For further information, please visit: http://www.imux.com.

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's three development programs and the targeted diseases; the potential for IMU-838 to safely and effectively target diseases; the proof-of-concept study of IMU-838 for the treatment of patients with primary sclerosing cholangitis; the timing of current and future clinical trials; the potential for IMU-838 as a treatment for primary sclerosing cholangitis that may be supported by the investigator-sponsored phase 2 proof-of-concept trial data, and any clinical trials, collaborations and approvals relating to such potential treatment; the nature, strategyand focus of the company; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020, the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 6, 2020, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc. Jessica BreuHead of Investor Relations and Communications+49 89 2080 477 09[emailprotected]

US IR ContactRx Communications GroupPaula Schwartz+1 917 322 2216[emailprotected]

US Media ContactKOGS CommunicationEdna Kaplan+1 781 639 1910[emailprotected]

SOURCE Immunic, Inc.

http://www.immunic-therapeutics.com

Read the original post:
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing...

Biochemistry Analysers Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the Competitors…

LOS ANGELES, United States:QY Research offers an encyclopedic study of the global Biochemistry Analysers market with holistic insights into vital factors and aspects that impact future market growth. The global Biochemistry Analysers market has been analyzed for the forecast period 2021-2027 and historical period 2015-2020. In order to help players to gain comprehensive understanding of the Global Biochemistry Analysers market and its critical dynamics, the research study provides detailed qualitative and quantitative analysis. Furthermore, readers are offered with complete and thorough research on different regions and segments of the global Biochemistry Analysers market. Almost all industry-specific, microeconomic, and macroeconomic factors influencing the global market growth have been analyzed in the report.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample-form/form/2537593/global-biochemistry-analysers-market

The competitive landscape of the global Biochemistry Analysers market is broadly studied in the report with large focus on recent developments, future plans of top players, and key growth strategies adopted by them. The analysts authoring the report have profiled almost every major player of the global Biochemistry Analysers market and thrown light on their crucial business aspects such as production, areas of operation, and product portfolio. All companies analyzed in the report are studied on the basis of vital factors such as market share, market growth, company size, production volume, revenue, and earnings.

Key Players Mentioned in the Global Biochemistry AnalysersMarket Research Report: Thermo Fisher Scientific, Abbott, HORIBA, Siemens Healthcare, Xylem Analytics, Agappe Diagnostics, RMS, MicroLab Instruments, Labindia Instruments

Global Biochemistry Analysers Market by Type: Fully Automated Biochemistry Analyser, Semi Automated Biochemistry Analyser

Global Biochemistry Analysers Market by Application: Hospital and Diagnostic Laboratories, Home Care, Academic and Research Institutes

The report offers great insights into important segments of the global Biochemistry Analysers market while concentrating on their CAGR, market size, market share, and future growth potential. The global Biochemistry Analysers market is mainly segmented according to type of product, application, and region. Each segment in these categories is extensively researched to become familiar with their growth prospects and key trends. Segmental analysis is highly important to identify key growth pockets of a global market. The report provides specific information on the market growth and demand of different products and applications to help players to focus on profitable areas of the global Biochemistry Analysers market.

Key Questions Answered by the Report

Request for customization in Report: https://www.qyresearch.com/customize-request/form/2537593/global-biochemistry-analysers-market

Table of Contents

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Read the rest here:
Biochemistry Analysers Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the Competitors...